Lead Product(s) : Ranitidine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions
Details : Ranitidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 27, 2010
Lead Product(s) : Ranitidine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranitidine
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity
Details : Ranitidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2017
Lead Product(s) : Ranitidine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
